|  |  |  | | | | Diseases | |  | Non-Hodgkin Lymphoma Trials |
| | |
| |  | Information Booklet |
A booklet produced by Leukaemia Research Fund giving background information on clinical trials is available to download.
Text version of the booklet
| Registers of Trials |
Current Controlled Trials
International Cancer Research Portfolio - a register of UK and US cancer research (including trials)
Last updated 03/12/2008
| Leukaemia Research sponsored trials |
There are no current LRF-sponsored trials on non-Hodgkin's lymphoma.
Last updated 25/11/2008
| Non-Leukaemia Research sponsored trials |
| A Randomised Study of Rituximab (Mabthera) in patients with Relapsed or Resistant Follicular Lymphoma prior to High Dose Therapy as In Vivo purging and to maintain remission following high dose therapy. | | Trial Code: | EBMT LYM1 | | Type: | Phase III | | Status: | Open | | Link: | http://www.controlled-trials.com/mrct/trial/|/1045... | | 1. To evaluate the effects of in vivo purging with rituximab and maintenance rituximab on time to disease progression in patients with relapsed follicular NHL undergoing high dose therapy. 2. To evaluate the effects of in vivo purging with rituximab and maintenance rituximab on response rate and overall survival in patients with relapsed or resistant follicular lymphoma undergoing high dose therapy 3. To evaluate the effect of in vivo purging with rituximab on molecular remission rates in the haemopoetic product and the patients 4. To evaluate the safety of rituximab in the transplant setting. |
| Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma - a phase III randomised clinical trial (Intergroup Collaborative Study). | | Trial Code: | ISRCTN65655917 | | Type: | Phase III | | Status: | Open | | Link: | http://www.controlled-trials.com/mrct/trial/|/1045... | | To establish in a prospective randomised clinical trial the effect of addition of chimeric anti-CD20 monoclonal antibody to CHOP chemotherapy on the response rate and quality (partial remission, complete remission, molecular complete remission) in relapsed low-grade non-Hodgkin's Lymphoma. To establish in a prospective randomised clinical trials the effect of maintenance treatment with chimeric anti-CD20 monoclonal antibody on progression free survival in relapsed low grade non-Hodgkin's lymphoma in remission after CHOP+/- Mabthera. |
| Phase III Trial comparing CHOP to PmitCEBO in Good Risk patients with Histologically Aggressive Non-Hodgkin's Lymphoma. | | Trial Code: | ISRCTN23628366 | | Type: | Phase III | | Status: | Open | | Link: | http://www.controlled-trials.com/mrct/trial/|/1045... | | 1. To compare the efficacy of PmitCEBO and CHOP in younger patients with good prognosis, histologically aggressive NHL in an open randomised trial using the study endpoint of overall survival between the groups randomised to PmitCEBO and CHOP. 2. Failure free survival, disease specific survival, relapse free survival, death due to toxicity, response rate and early and late toxicity. |
| BNLI Randomised trial of Radiation dose in Non-Hodgkin's Lymphoma | | Trial Code: | ISRCTN71826974 | | Type: | Phase III | | Status: | Open | | Link: | http://www.controlled-trials.com/mrct/trial/|/1045... | | Primary endpoint is local control. Secondary endpoints are local morbidity (skin reactions, mucositis, bone marrow depression, gastrointestinal upset for infradiaphragmatic field, dysphagia for supradiaphragmatic fields). |
Last updated 25/11/2008 |
|
|
|
